Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease severe eczema itch and rash

NCT ID NCT07216027

Symptom relief Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic visits and tests. The goal is to see if the drug can reduce symptoms like rash and severe itching.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet the following criteria: 1. Are 18 to 64 years of age 2. Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs 3. Have moderate to severe AD as defined by the following at screening and baseline visits: * Affected body surface area (BSA) greater than or equal to 10% and up to 60%; * Validated Investigator's Global Assessment (vIGA) greater than or equal to 3; * Eczema Area and Severity Index (EASI) greater than or equal to 16; AND -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit 4. Do not have a suitable prescribed medicine for AD. 5. Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs) Exclusion Criteria: Participants must not meet the following criteria: 1. Have an infection that requires treatment 2. Have other skin conditions other than AD 3. Have severe uncontrolled asthma 4. Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Eczema, atopic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre de Recherche Saint-Louis inc.

    RECRUITING

    Québec, G1W 4R4, Canada

  • Clinical Science Institute

    ACTIVE_NOT_RECRUITING

    Santa Monica, California, 90403, United States

  • Dermatology and Ophthalmology Kume Clinic

    RECRUITING

    Sakai, Osaka, 593-8324, Japan

  • Fukuwa Clinic

    RECRUITING

    Chuo-ku, Tokyo, 104-0031, Japan

  • Gsi Clinical Research

    RECRUITING

    Margate, Florida, 33063, United States

  • Hattori Dermatology Clinic

    RECRUITING

    Takasaki, Gunma, 370-0071, Japan

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Kosugi Dermatology Clinic

    RECRUITING

    Kawasaki-shi, Kanagawa, 211-0063, Japan

  • Marvel Clinical Research

    RECRUITING

    Huntington Beach, California, 92647, United States

  • Mayo Clinic in Arizona - Scottsdale

    NOT_YET_RECRUITING

    Scottsdale, Arizona, 85259, United States

  • Metropolis Dermatology - DTLA

    NOT_YET_RECRUITING

    Los Angeles, California, 90017, United States

  • Montefiore - Clinical Research Center

    RECRUITING

    The Bronx, New York, 10467, United States

  • Montefiore - Greene Medical Arts Pavillion

    RECRUITING

    The Bronx, New York, 10467, United States

  • Montefiore - Jacobi Dermatology Clinic

    RECRUITING

    The Bronx, New York, 10461, United States

  • Montefiore - The Dermatology Center

    RECRUITING

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

  • Nihonbashi Sakura Clinic

    RECRUITING

    Chuo-ku, Tokyo, 103-0025, Japan

  • Northridge Clinical Trials

    RECRUITING

    Northridge, California, 91325, United States

  • Paddington Testing Co, Inc

    RECRUITING

    Philadelphia, Pennsylvania, 19103, United States

  • Peking University People's Hospital

    NOT_YET_RECRUITING

    Beijing, 100044, China

  • Queen's square Medical Facilities Queen's square Dermatology and Allergology

    RECRUITING

    Yokohama, Kanagawa, 220-6208, Japan

  • Skin Research of South Florida

    ACTIVE_NOT_RECRUITING

    Miami, Florida, 33173, United States

  • UPMC Department of Dermatology

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.